Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

April 10, 2019

Trial Testing Triple Combo Immunotherapy in Newly-diagnosed Glioblastoma Completes Patient Enrollment

News

A Phase 1/2 clinical trial testing a triple immunotherapy combination for newly diagnosed glioblastoma has completed patient enrollment three months ahead of schedule. Inovio Pharmaceuticals, the company leading the ... Read more

April 9, 2019

OSE Immunotherapeutics, Léon Bérard Cancer Center to Collaborate Using AI

News

France’s OSE Immunotherapeutics and Léon Bérard Cancer Center have established a research collaboration to use analysis based on artificial intelligence (AI) to identify new targets for cancer immunotherapies. Under the ... Read more

April 3, 2019

Phase 1 Study Begins Dosing High-Grade Glioma Patients with GMCI Combo Therapy

News

A Phase 1 study has started dosing patients who have newly diagnosed high-grade gliomas with a combination of Candel Therapeutics‘ gene-mediated cytotoxic immunotherapy (GMCI) plus Opdivo (nivolumab) and standard ... Read more

March 26, 2019

Collaboration to Explore How Gut Bacteria Might Bolster Immunotherapy

News

Seres Therapeutics and AstraZeneca have established a research collaboration to unravel the mechanisms by which the microbiome – the natural, beneficial community of microbes living in the gut — ... Read more

March 5, 2019

FDA Grants Priority Review to Keytruda for Advanced Small Cell Lung Cancer

News

The U.S. Food and Drug Administration has accepted Merck‘s application seeking accelerated approval of Keytruda (pembrolizumab) for the treatment of advanced small cell lung cancer (SCLC) patients who failed at least two prior ... Read more

February 26, 2019

First Mesothelioma Patient Dosed in Phase 1 Trial of Curis’ CA-170

News

The Phase 1 trial evaluating Curis‘ investigational immunotherapy CA-170 for advanced cancers has dosed its first mesothelioma patient, the company announced. The trial (NCT02812875), currently enrolling participants, will test the therapy in ... Read more

February 19, 2019

European Panel Favors Approval of Keytruda-Chemo Combo as First-line Therapy for NSCLC

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda (pembrolizumab) in combination with chemotherapy for the initial ... Read more

January 30, 2019January 30, 2019

Nanobiotix Plans Nine NBTXR3 Clinical Trials for Six Cancer Types

News

Nanobiotix is planning to conduct nine Phase 1/2 clinical trials in collaboration with the University of Texas MD Anderson Cancer Center to study the company’s investigational compound NBTXR3. The trials, which will ... Read more

January 29, 2019January 29, 2019

Keytruda Reduces Risk of Death in Some Patients with Advanced Esophageal Cancer, Study Shows

News

Second-line treatment with Keytruda (pembrolizumab) significantly extends the lives of advanced esophageal cancer and esophagogastric junction carcinoma patients whose tumors are positive for the PD-L1 factor, a Phase 3 clinical ... Read more

January 23, 2019January 23, 2019

FDA to Review Tecentriq Triple Combo as First-Line Treatment for Certain NSCLC Patients

News

The U.S. Food and Drug Administration will review Genentech‘s Tecentriq (atezolizumab), in combination with chemotherapy medications Abraxane (nab-paclitaxel) and carboplatin, as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC), the company ... Read more

Pin It on Pinterest